Last reviewed · How we verify
IFN-K
At a glance
| Generic name | IFN-K |
|---|---|
| Sponsor | Neovacs |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study Designed to Evaluate the Effect of CimetrA in Patients Diagnosed With COVID-19 (PHASE2)
- A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection (PHASE2, PHASE3)
- A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-administration of ABT-493 and ABT-530 With and Without Ribavirin in Subjects With HCV Genotype 1, 4, 5, and 6 Infection (PHASE2)
- A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 Coinfection (PHASE2, PHASE3)
- Phase IIb Study of IFN-K in Systemic Lupus Erythematosus (PHASE2)
- Study of IFN-K in Dermatomyositis (PHASE2)
- Safety of IFNa Kinoid in Systemic Lupus Erythematosus (PHASE1, PHASE2)
- Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IFN-K CI brief — competitive landscape report
- IFN-K updates RSS · CI watch RSS
- Neovacs portfolio CI